Global Cyclodextrins In Pharma Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2022 –2029 |
 Tamaño del mercado (año base) |
USD 270.40 Million |
 Tamaño del mercado (año de pronóstico) |
USD 370.06 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado global de ciclodextrinas en la industria farmacéutica , por tipo (Β ciclodextrina, 2-hidroxipropil-Β-ciclodextrina, Α ciclodextrina, γ-ciclodextrina, Β-ciclodextrina metilada aleatoriamente, Β-ciclodextrina sulfobutiléter, 2-hidroxipropil-Γ-ciclodextrina), estructura (conjugados de ciclodextrina, portadores de fármacos mucoadhesivos, asociados de ciclodextrina, ciclodextrinas anfifílicas, otros), naturaleza (hidrófila, hidrófoba ), forma (sólida, líquida), aplicación (solubilidad y disolución de fármacos, biodisponibilidad de fármacos, seguridad de fármacos, estabilidad de fármacos, otros), área terapéutica (manejo del dolor, enfermedades cardiovasculares, trastornos del comportamiento, terapia del cáncer, artritis reumatoide, epilepsia, tipo de enfermedad de Niemann Pick) C (NPC), Otros), Canal de distribución (Licitación directa, Ventas minoristas, Otros): tendencias de la industria y pronóstico hasta 2029
Análisis y tamaño del mercado
En los últimos años, se prevé que el mercado de las ciclodextrinas en la industria farmacéutica crezca rápidamente durante el período de pronóstico. Las ciclodextrinas son moléculas de azúcar a base de almidón con un interior lipofílico y una capa exterior hidrófila. Debido a sus propiedades antienvejecimiento, la ciclodextrina tiene una gran demanda entre los fabricantes de cosméticos. Se utiliza ampliamente en la fabricación de cosméticos y artículos de cuidado personal como cremas, mascarillas faciales y lociones, entre otras cosas, y se espera que impulse la expansión del mercado en los próximos años. Mientras tanto, es probable que la creciente popularidad de los suplementos dietéticos para estimular la inmunidad general en todo el mundo impulse la expansión del mercado en el período de pronóstico.
Data Bridge Market Research analiza que el mercado de ciclodextrinas en la industria farmacéutica se valoró en USD 270,40 millones en 2021 y se espera que alcance los USD 370,06 millones para 2029, registrando una CAGR del 4,00% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.
Definición de mercado
Las ciclodextrinas son un tipo de azúcar cíclico complejo formado por un anillo macrocíclico de subunidades de glucosa unidas entre sí por enlaces glucosídicos alfa-1,4. La ciclodextrina se forma cuando un almidón se descompone enzimáticamente en moléculas simples. La ciclodextrina se utiliza cada vez más en las industrias farmacéutica y química como componente disolvente en la administración de medicamentos. La ciclodextrina se utiliza para aumentar la solubilidad en agua, la estabilidad y la biodisponibilidad de los medicamentos encapsulando moléculas medicinales hidrofóbicas en sistemas biológicos.
Alcance del informe y segmentación del mercado
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2022 a 2029 |
|
Año base |
2021 |
|
Años históricos |
2020 (Personalizable para 2019 - 2014) |
|
Unidades cuantitativas |
Ingresos en millones de USD, volúmenes en unidades, precios en USD |
|
Segmentos cubiertos |
Tipo (Β ciclodextrina, 2-hidroxipropil-Β-ciclodextrina, Α ciclodextrina, γ-ciclodextrina, Β-ciclodextrina metilada aleatoriamente, Β-ciclodextrina sulfobutiléter, 2-hidroxipropil-Γ-ciclodextrina), Estructura (conjugados de ciclodextrina, portadores de fármacos mucoadhesivos, asociados de ciclodextrina, ciclodextrinas anfifílicas, otros), Naturaleza (hidrófila, hidrófoba), Forma (sólida, líquida), Aplicación (solubilidad y disolución de fármacos, biodisponibilidad de fármacos, seguridad de fármacos, estabilidad de fármacos, otros), Área terapéutica (manejo del dolor, enfermedades cardiovasculares, trastorno del comportamiento, terapia del cáncer, artritis reumatoide, epilepsia, enfermedad de Niemann Pick tipo C (NPC), otros), Canal de distribución (directo Licitación, Ventas Minoristas, Otros) |
|
Países cubiertos |
EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur |
|
Actores del mercado cubiertos |
Cambrex Corporation (EE. UU.), Cayman Chemical (EE. UU.), Wellona Pharma (India), Wacker Chemie AG (Alemania), Cyclolab (Hungría), Tocopharm Co. Limited (China), Roquette Frères (Francia), Midas Pharma GmbH (Alemania), Ligand Pharmaceuticals Incorporated (EE. UU.), Cyclo Therapeutics, Inc. (EE. UU.), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Alemania), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Suiza), Ashland (EE. UU.), TCI Chemicals (India) Pvt. Ltd. (Japón) |
|
Oportunidades de mercado |
|
Dinámica del mercado de ciclodextrinas en la industria farmacéutica
Conductores
- Aumento del consumo de suplementos dietéticos
Se estima que el aumento del consumo de suplementos dietéticos impulsará el crecimiento del mercado. Los excipientes como la ciclodextrina se utilizan en formulaciones farmacéuticas y nutracéuticas. Como resultado de la pandemia de COVID-19, los médicos han recetado una variedad de medicamentos antivirales a los pacientes para ayudarlos a combatir el virus desde el principio. El uso creciente de estos medicamentos ha impulsado el consumo de ciclodextrina, lo que ha impulsado el crecimiento del mercado durante el período de pronóstico.
- Aumentar la inversión en infraestructura sanitaria
Otro factor importante que influye en la tasa de crecimiento de las ciclodextrinas en el mercado farmacéutico es el aumento del gasto sanitario, que contribuye a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cyclodextrins in pharma market. Additionally, the rapidly changing consumer attitudes toward health and the growing use of cyclodextrins in renal diseases will also result in the expansion of cyclodextrins in pharma market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cyclodextrins in pharma market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the cyclodextrins in pharma market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with drug distribution and development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cyclodextrins in pharma market. Additionally, strict regulatory policies coupled with the barriers to conducting diagnostics tests will restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This cyclodextrins in pharma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclodextrins in pharma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cyclodextrins in pharma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cyclodextrins in Pharma Market
Desde su aparición en diciembre de 2019, el virus COVID-19 se ha propagado a casi todos los países del planeta, lo que llevó a la Organización Mundial de la Salud (OMS) a declararlo una emergencia de salud pública. El COVID-19, un nuevo coronavirus, fue identificado como el agente causal de los casos de neumonía. Este virus se propagó rápidamente por todo el mundo y mató a un gran número de personas. La Organización Mundial de la Salud (OMS) calificó al COVID-19 como una pandemia mundial en marzo de 2020 y recomendó medidas rigurosas para prevenir la propagación de la enfermedad. Desde entonces, la pandemia ha retrasado la expansión del sector sanitario y ha interrumpido la cadena de suministro. Además, los gobiernos de muchos países habían impuesto confinamientos a nivel nacional para detener la propagación del COVID-19. Del mismo modo, las organizaciones sanitarias de numerosos países de todo el mundo tenían dificultades para continuar con sus actividades de la cadena de suministro. El mercado de las ciclodextrinas en la industria farmacéutica se vio obstaculizado por la lentitud de la cadena de suministro. Sin embargo, ahora que las vacunas contra el COVID-19 están fácilmente disponibles, numerosas autoridades están tratando de garantizar que los medicamentos y las vacunas que salvan vidas se suministren sin interrupción. Como resultado, se proyecta que el mercado se estabilizará en el futuro.
Alcance del mercado mundial de ciclodextrinas en la industria farmacéutica
El mercado de las ciclodextrinas en la industria farmacéutica está segmentado en función del tipo, la estructura, la naturaleza, la forma, la aplicación, las áreas terapéuticas y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los escasos segmentos de crecimiento de las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Tipo
- B-ciclodextrina
- 2-Hidroxipropil-Β-Ciclodextrina
- Una ciclodextrina
- γ-ciclodextrina
- Β-ciclodextrina metilada aleatoriamente
- Sulfobutiléter Β-Ciclodextrina
- 2-Hidroxipropil-Γ-Ciclodextrina
Estructura
- Conjugados de ciclodextrina
- Portadores de fármacos mucoadhesivos
- Asociados de ciclodextrina
- Ciclodextrinas anfifílicas
- Otros
Naturaleza
- Hidrofílico
- Hidrofóbico
Forma
- Sólido
- Líquido
Solicitud
- Solubilidad y disolución de fármacos
- Biodisponibilidad de los fármacos
- Seguridad de los medicamentos
- Estabilidad del fármaco
- Otros
Área Terapéutica
- Manejo del dolor
- Enfermedades cardiovasculares
- Trastorno del comportamiento
- Terapia contra el cáncer
- Artritis reumatoide
- Epilepsia
- Enfermedad de Niemann-Pick tipo C (NPC)
- Otros
Canal de distribución
- Licitación directa
- Ventas al por menor
- Otros
Análisis y perspectivas regionales del mercado de ciclodextrinas en la industria farmacéutica
Se analiza el mercado de ciclodextrinas en la industria farmacéutica y se proporcionan información y tendencias del tamaño del mercado por país, tipo, estructura, naturaleza, forma, aplicación, áreas terapéuticas y canal de distribución como se mencionó anteriormente.
Los países cubiertos en el informe del mercado de ciclodextrinas en la industria farmacéutica son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de Sudamérica como parte de Sudamérica.
América del Norte domina el mercado farmacéutico de las ciclodextrinas debido a los nuevos fármacos líderes en farmacología basados en ciclodextrinas en esta región. Además, el aumento del gasto sanitario y la creciente demanda de tratamientos específicos para enfermedades impulsarán aún más la tasa de crecimiento del mercado en esta región.
Se espera que Asia-Pacífico crezca durante el período de pronóstico de 2022 a 2029 debido a la creciente demanda de compuestos de ciclodextrina para productos farmacéuticos en esta región. Además, el desarrollo de la infraestructura de atención médica y las crecientes iniciativas gubernamentales impulsarán aún más la tasa de crecimiento del mercado en esta región.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de las ciclodextrinas en el sector farmacéutico
El panorama competitivo del mercado de ciclodextrinas en la industria farmacéutica proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de ciclodextrinas en la industria farmacéutica.
Algunos de los principales actores que operan en el mercado de ciclodextrinas en la industria farmacéutica son:
- Corporación Cambrex (Estados Unidos)
- Cayman Chemical (Estados Unidos)
- Wellona Pharma (India)
- Wacker Chemie AG (Alemania)
- Cyclolab (Hungría)
- Tocopharm Co. Ltd (China)
- Roquette Frères (Francia)
- Midas Pharma GmbH (Alemania)
- Ligand Pharmaceuticals Incorporated (Estados Unidos)
- Cyclo Therapeutics, Inc. (Estados Unidos)
- Zibo Qianhui Tecnología biológica Co., Ltd. (China)
- Industria bioquímica de Xi'an Deli Co., Ltd (China)
- Merck KGaA (Alemania)
- Otto Chemie Pvt. Ltd. (India)
- VIO CHEMICALS (Suiza)
- Ashland (Estados Unidos)
- TCI Chemicals (India) Pvt. Ltd. (Japón)
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 THERAPEUTIC AREAS LIFELINE CURVE
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATIONS
5.1 FDA
5.2 JAPAN
6 IMPACT OF COVID-19 ON GLOBAL CYCLODEXTRIN IN PHARMA MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS
7.1.2 INCREASING DRUG STABILITY
7.1.3 USE OF CYCLODEXTRIN IN DRUG DELIVERY
7.1.4 LAUNCH OF FINISHED PRODUCTS OF CYCLODEXTRIN
7.1.5 RISING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 HIGH COSTS OF CYCLODEXTRIN
7.2.2 TOXICITY STUDIES OF CYCLODEXTRINS
7.3 OPPORTUNITIES
7.3.1 INCREASING RESEARCH OF CYCLODEXTRIN IN COVID-19 TREATMENT
7.3.2 RISING USE OF CYCLODEXTRIN IN RENAL DISEASES
7.3.3 RISING INVESTMENT ON RESEARCH ACTIVITIES
7.3.4 INCREASES AWARENESS ABOUT THE USE OF CYCLODEXTRIN IN PHARMA INDUSTRY
7.4 CHALLENGES
7.4.1 LIMITATION OF CYCLODEXTRIN IN OPTHALMIC USE
7.4.2 USE OF VARIOUS TECHNIQUES IN MANUFACTURING CYCLODEXTRIN
8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE
8.1 OVERVIEW
8.1.1 Β CYCLODEXTRIN
8.1.2 2-HYDROXYPROPYL-Β-CYCLODEXTRIN
8.1.3 Α CYCLODEXTRIN
8.1.4 Γ-CYCLODEXTRIN
8.1.5 RANDOMLY METHYLATED Β-CYCLODEXTRIN
8.1.6 SULFOBUTYLETHER Β-CYCLODEXTRIN
8.1.7 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN
9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE
9.1 OVERVIEW
9.2 CYCLODEXTRIN CONJUGATES
9.2.1 POLYMERS
9.2.2 NANOSPONGES
9.3 MUCOADHESIVE DRUG CARRIERS
9.3.1 POLYETHYLENE-GLYCOL
9.3.2 CHITOSAN
9.3.3 ALGINATE
9.4 CYCLODEXTRIN ASSOCIATES
9.4.1 POLYPSEUDOROTAXANES
9.4.2 POLYROTAXANES
9.5 AMPHIPHILIC CYCLODEXTRINS
9.5.1 POLYSUBSTITUTED
9.5.2 MONOSUBSTITUTED
9.6 OTHERS
10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM
10.1 OVERVIEW
10.2 SOLID
10.3 LIQUID
11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE
11.1 OVERVIEW
11.2 HYDROPHILIC
11.3 HYDROPHOBIC
12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DRUG SOLUBILITY AND DISSOLUTION
12.3 DRUG BIOAVAILABILITY
12.4 DRUG SAFETY
12.5 DRUG STABILITY
12.6 OTHERS
13 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS
13.1 OVERVIEW
13.2 PAIN MANAGEMENT
13.3 CARDIOVASCULAR DISEASES
13.4 BEHAVIORAL DISORDER
13.5 CANCER THERAPY
13.6 RHEUMATOID ARTHRITIS
13.7 EPILEPSY
13.8 NIEMANN PICK DISEASE TYPE C (NPC)
13.9 OTHERS
14 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.4 OTHERS
15 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY GEOGRAPHY
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K
15.3.4 ITALY
15.3.5 NETHERLANDS
15.3.6 SPAIN
15.3.7 RUSSIA
15.3.8 SWITZERLAND
15.3.9 BELGIUM
15.3.10 TURKEY
15.3.11 AUSTRIA
15.3.12 NORWAY
15.3.13 HUNGARY
15.3.14 LITHUANIA
15.3.15 IRELAND
15.3.16 POLAND
15.3.17 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 INDIA
15.4.4 SOUTH KOREA
15.4.5 AUSTRALIA
15.4.6 SINGAPORE
15.4.7 MALAYSIA
15.4.8 THAILAND
15.4.9 INDONESIA
15.4.10 PHILIPPINES
15.4.11 VIETNAM
15.4.12 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ARGENTINA
15.5.3 PERU
15.5.4 REST OF SOUTH AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 SAUDI ARABIA
15.6.2 SOUTH AFRICA
15.6.3 UAE
15.6.4 ISRAEL
15.6.5 EGYPT
15.6.6 KUWAIT
15.6.7 REST OF MIDDLE EAST & AFRICA
16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT
18 COMPANY PROFILE
18.1 ROQUETTE FRÈRES
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 LIGAND PHARMACEUTICALS INCORPORATED
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 TECHNOLOGY PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 WACKER CHEMIE AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK KGAA
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 CYCLOLAB
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 CAMBREX CORPORATION
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 CAYMAN CHEMICAL
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 CYCLO THERAPEUTICS, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 MIDAS PHARMA GMBH
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 TOCOPHARM CO. LIMITED
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 WELLONA PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 XI'AN DELI BIOCHEMICAL INDUSTRY CO.,LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 ZIBO QIANHUI BIOLOGICAL TECHNOLOGY CO.,LTD
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT
TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN
TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN
TABLE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)
TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 6 GLOBAL 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 7 GLOBAL Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 8 GLOBAL Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 9 GLOBAL RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 10 GLOBAL SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 11 GLOBAL 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)
TABLE 13 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 14 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 15 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 16 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 17 GLOBAL CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 18 GLOBAL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 19 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 20 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)
TABLE 23 GLOBAL SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 24 GLOBAL LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)
TABLE 26 GLOBAL HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 27 GLOBAL HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)
TABLE 29 GLOBAL DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 30 GLOBAL DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 31 GLOBAL DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 32 GLOBAL DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 33 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)
TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 48 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 49 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 50 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 51 NORTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 52 NORTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 53 NORTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 54 NORTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 56 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 57 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 58 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 59 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 60 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 61 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 62 U.S. CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 63 U.S. CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 64 U.S. MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 65 U.S. AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 66 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 67 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 68 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 69 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 70 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 71 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 72 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 73 CANADA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 74 CANADA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 75 CANADA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 76 CANADA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 77 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 78 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 79 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 80 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 81 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 82 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 83 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 84 MEXICO CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 85 MEXICO CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 86 MEXICO MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 87 MEXICO AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 88 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 89 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 90 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 91 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 92 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 93 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 94 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 95 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 96 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 97 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 98 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 99 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 100 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 101 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 102 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 103 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 104 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 105 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 106 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 107 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 108 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 109 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 110 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 111 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 112 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 113 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 114 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 115 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 116 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 117 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 118 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 119 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 120 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 121 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 122 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 123 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 124 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 125 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 126 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 127 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 128 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 129 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 130 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 131 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 132 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 133 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 134 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 135 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 136 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 137 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 138 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 139 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 140 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 141 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 142 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 143 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 144 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 145 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 146 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 147 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 148 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 149 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 150 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 151 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 152 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 153 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 154 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 155 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 156 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 157 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 158 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 159 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 160 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 161 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 162 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 163 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 164 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 165 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 166 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 167 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 168 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 169 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 170 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 171 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 172 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 173 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 174 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 175 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 176 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 177 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 178 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 179 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 180 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 181 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 182 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 183 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 184 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 185 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 186 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 187 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 188 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 189 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 190 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 191 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 192 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 193 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 194 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 195 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 196 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 197 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 198 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 199 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 200 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 201 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 202 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 203 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 204 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 205 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 206 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 207 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 208 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 209 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 210 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 211 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 212 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 213 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 214 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 215 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 216 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 217 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 218 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 219 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 220 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 221 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 222 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 223 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 224 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 225 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 226 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 227 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 228 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 229 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 230 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 231 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 232 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 233 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 234 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 235 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 236 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 237 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 238 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 239 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 240 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 241 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 242 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 243 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 244 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 245 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 246 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 247 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 248 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 249 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 250 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 251 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 252 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 253 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 254 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 255 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 256 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 257 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 258 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 259 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 260 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 261 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 262 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 263 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 264 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 265 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 266 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 267 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 268 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 269 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 270 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 271 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 272 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 273 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 274 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 275 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 276 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 277 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 278 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 279 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 280 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 281 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 294 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 295 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 296 JAPAN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 297 JAPAN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 298 JAPAN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 299 JAPAN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 300 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 301 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 302 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 303 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 304 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 305 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 306 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 307 CHINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 308 CHINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 309 CHINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 310 CHINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 311 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 312 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 313 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 314 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 315 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 316 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 317 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 318 INDIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 319 INDIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 320 INDIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 321 INDIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 322 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 323 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 324 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 325 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 326 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 327 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 328 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 329 SOUTH KOREA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 330 SOUTH KOREA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 331 SOUTH KOREA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 332 SOUTH KOREA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 333 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 334 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 335 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 336 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 337 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 338 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 339 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 340 AUSTRALIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 341 AUSTRALIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 342 AUSTRALIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 343 AUSTRALIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 344 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 345 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 346 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 347 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 348 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 349 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 350 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 351 SINGAPORE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 352 SINGAPORE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 353 SINGAPORE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 354 SINGAPORE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 355 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 356 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 357 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 358 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 359 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 360 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 361 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 362 MALAYSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 363 MALAYSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 364 MALAYSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 365 MALAYSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 366 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 367 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 368 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 369 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 370 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 371 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 372 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 373 THAILAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 374 THAILAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 375 THAILAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 376 THAILAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 377 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 378 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 379 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 380 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 381 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 382 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 383 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 384 INDONESIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 385 INDONESIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 386 INDONESIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 387 INDONESIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 388 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 389 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 390 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 391 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 392 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 393 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 394 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 395 PHILIPPINES CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 396 PHILIPPINES CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 397 PHILIPPINES MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 398 PHILIPPINES AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 399 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 400 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 401 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 402 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 403 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 404 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 405 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 406 VIETNAM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 407 VIETNAM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 408 VIETNAM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 409 VIETNAM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 410 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 411 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 412 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 413 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 414 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 415 REST OF ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 416 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 417 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 418 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 419 SOUTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 420 SOUTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 421 SOUTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 422 SOUTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 423 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 424 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 425 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 426 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 427 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 428 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 429 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 430 BRAZIL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 431 BRAZIL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 432 BRAZIL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 433 BRAZIL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 434 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 435 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 436 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 437 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 438 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 439 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 440 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 441 ARGENTINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 442 ARGENTINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 443 ARGENTINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 444 ARGENTINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 445 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 446 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 447 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 448 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 449 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 450 PERU CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 451 PERU CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 452 PERU CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 453 PERU CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 454 PERU MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 455 PERU AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 456 PERU CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 457 PERU CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 458 PERU CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 459 PERU CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 460 PERU CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 461 REST OF SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 462 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 463 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 464 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 465 MIDDLE EAST & AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 466 MIDDLE EAST & AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 467 MIDDLE EAST & AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 468 MIDDLE EAST & AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 469 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 470 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 471 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 472 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 473 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 474 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 475 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 476 SAUDI ARABIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 477 SAUDI ARABIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 478 SAUDI ARABIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 479 SAUDI ARABIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 480 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 481 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 482 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 483 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 484 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 485 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 486 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 487 SOUTH AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 488 SOUTH AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 489 SOUTH AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 490 SOUTH AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 491 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 492 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 493 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 494 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 495 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 496 UAE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 497 UAE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 498 UAE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 499 UAE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 500 UAE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 501 UAE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 502 UAE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 503 UAE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 504 UAE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 505 UAE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 506 UAE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 507 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 508 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 509 ISRAEL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 510 ISRAEL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 511 ISRAEL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 512 ISRAEL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 513 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 514 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 515 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 516 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 517 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 518 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 519 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 520 EGYPT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 521 EGYPT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 522 EGYPT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 523 EGYPT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 524 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 525 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 526 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 527 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 528 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 529 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 530 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 531 KUWAIT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 532 KUWAIT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 533 KUWAIT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 534 KUWAIT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 535 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 536 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 537 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 538 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 539 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 540 REST OF MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
Lista de figuras
LIST OF FIGURES
FIGURE 1 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION
FIGURE 2 GLOBAL CYCLODEXTRINS IN PHARMA MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DBMR MARKET POSITION GRID
FIGURE 10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS AND INCREASES DRUG STABILITY IS DRIVING THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 B CYCLODEXTRIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, PIPELINE ANALYSIS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET
FIGURE 18 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019
FIGURE 19 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 20 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 21 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019
FIGURE 23 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019-2027 (USD THOUSAND)
FIGURE 24 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, CAGR (2020-2027)
FIGURE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019
FIGURE 27 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019-2027 (USD THOUSAND)
FIGURE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, CAGR (2020-2027)
FIGURE 29 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, LIFELINE CURVE
FIGURE 30 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019
FIGURE 31 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019-2027 (USD THOUSAND)
FIGURE 32 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, CAGR (2020-2027)
FIGURE 33 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, LIFELINE CURVE
FIGURE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019
FIGURE 35 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019-2027 (USD THOUSAND)
FIGURE 36 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 37 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 39 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)
FIGURE 40 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 41 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 42 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 44 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 45 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019)
FIGURE 48 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2020 & 2027)
FIGURE 49 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019 & 2027)
FIGURE 50 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 51 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 52 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 53 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 54 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 56 EUROPE CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 57 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 58 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 59 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 60 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 61 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 62 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 63 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 64 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 65 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 66 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 67 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 68 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 71 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 72 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 73 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 76 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 77 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 78 EUROPE CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 79 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKETMARKET: COMPANY SHARE 2019 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
